PA-MONROL
Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) today announced their agreement with Molecular Targeting Technologies, Inc. (MTTI), a clinical stage biotech company focused on developing innovative therapies for rare cancers, for the supply of the medical radioisotope no-carrier-added 177 Lu (n.c.a. 177 Lu).
Eczacıbaşı-Monrol entered the theranostic market in 2019 as one of the few producers of Lutetium-177 worldwide and since then has provided an uninterrupted supply of this critical product to patients in many countries. In line with its mission to improve the quality of life of cancer patients globally, the company is establishing strategic partnerships with international pharmaceutical companies and constructing a new production facility compliant with FDA 21 CFR Part 211 quality standards that will have an annual capacity of 60 thousand doses. Thanks to its location close to Istanbul's transportation hub, the new facility will benefit from a worldwide logistics network and agreements with cargo services to 320 destinations worldwide.
Aydin Küçük, General Manager of Eczacıbaşı-Monrol, noted that n.c.a.177 Lu contributes to the company's mission of adding value to human life with leading and innovative approaches in the diagnosis and treatment of critical diseases and added, "To support our growth in this field, we're establishing a new GMP certified facility exclusively for theranostic R&D and production with a new technology that will enable us to maximize our supply of high-quality Lutetium. Sustainability and innovation are two of our core values, and we strive for continuous improvement in our operations and products while trying to serve patients all around the world."
Molecular Targeting Technologies, Inc. (MTTI) CEO, Chris Pak said, " We’ve identified a timely and sustainable supply of a key therapeutic ingredient needed for the development and launch of our lead asset 177 Lu-EBTATE and other EB platform technologies. We are excited to start
this collaboration and build what promises to be a great relationship with a reliable and trusted radioisotope supply partner like Eczacıbaşı-Monrol for the supply of n.c.a.177 Lu.”
About Molecular Targeting Technologies, Inc. (MTTI)
Molecular Targeting Technologies, Inc. is a privately held, rapidly growing, well financed, clinical stage biotech developing targeted radiotherapeutics and diagnostics for rare cancers. We are committed to building value by acquiring and translating innovative imaging, radiopharmaceutical and theranostic assets to improve human health, reduce healthcare costs and reward stakeholders. MTTI expects to be orchestrating multiple clinical trials in 2022. For more information: www.mtarget.com
; www.evathera.com
About Eczacıbaşı-Monrol
Eczacıbaşı-Monrol Nuclear Products Co. is an innovative, international supplier of radiopharmaceuticals for diagnosis and treatment in nuclear medicine. Eczacıbaşı-Monrol is headquartered in Istanbul and delivers customer-oriented service globally.
Monrol exports high quality and a wide spectrum of nuclear medicine products to more than 50 countries around the globe and has manufacturing sites and operational projects in different regions. For more information visit www.monrol.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123006032/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Copeland Advances AI and Digital Strategy with Acquisition of Bueno Analytics21.1.2026 13:00:00 CET | Press release
Acquisition integrates advanced SaaS capabilities to deliver smarter, data‑driven HVAC and cold chain solutions Copeland, a global provider of compression technologies and controls solutions, announced today that it has entered into an agreement to acquire Bueno Analytics (“Bueno”), an Australia-based company specializing in SaaS solutions that leverage embedded AI and machine learning to deliver building analytics, energy management and operational efficiency across commercial buildings and the cold chain. Bueno’s platform is deployed across several thousand customer sites worldwide, providing broad connectivity, full portfolio visibility and critical operational insights. Buildings account for an estimated 40% of global carbon emissions, with commercial buildings and the cold chain representing a significant share of that impact. The integration of Bueno’s platform with Copeland’s deep domain expertise will deliver a powerful suite of capabilities, including predictive maintenance, e
NIRSense, Inc. & Aspen Medical USA (AMUSA): Strengthening Frontline Medicine: U.S.–Developed Tissue Oxygenation Technology Delivered to Ukraine21.1.2026 13:00:00 CET | Press release
Today, NIRSense and Aspen Medical USA (AMUSA) are pleased to announce the donation of 12 portable tissue-ischemia monitoring kits (comprising advanced sensor consoles plus tablets) to the Ministry of Defence of Ukraine (MoD) for deployment in frontline Role-1 and Role-2 casualty care facilities in Ukraine. These investigational prototype systems are provided for use by military medical teams treating extremity-injured personnel (including those who have undergone tourniquet application) to assess and monitor tissue perfusion and oxygenation in real time. Why this matters In the battlefield context, timely recognition of compromised tissue perfusion (particularly in limbs subject to tourniquet use, major soft‐tissue injury or ischemia-reperfusion risk) can make the difference between viable salvage of the limb, avoidance of secondary complications, and optimal patient outcomes. The donated NIRSense kits, which will be administered by the Ukraine MoD under an approved protocol, may provi
Allshares Acquires U.S. Market Leader Stock & Option Solutions, Solidifying Its Position as a Global Leader in Equity Ownership Management21.1.2026 12:00:00 CET | Press release
Allshares, a global provider of equity ownership management software and services, today announced the acquisition of Stock & Option Solutions (“SOS” or the “Company”), a U.S.-based specialist in end-to-end equity compensation and plan administration. Stock & Option Solutions brings a track record of supporting the full life cycle of equity and compensation plan administration. Recognized as one of the Inc. 5000 fastest-growing companies in 2022, the Company has built a strong reputation for supporting organizations across the United States, from early-stage startups to large enterprises. Its platform-agnostic service model enables clients to optimize complex incentive structures across major equity technology systems. This acquisition marks a strategic milestone in Allshares’ expansion, establishing the U.S. as Allshares’ largest and fastest-growing market. By integrating SOS’ deep U.S. expertise, Allshares strengthens its ability to deliver seamless ownership management for clients o
WEF26: ‘Human Capital Is the Key Driver of Economic Competitiveness’21.1.2026 10:33:00 CET | Press release
For economies to remain competitive in the future, they must prioritize investments in human capital, Her Royal Highness Princess Reema Bandar Al-Saud, Ambassador of the Kingdom of Saudi Arabia to the United States of America, told the World Economic Forum (WEF) Annual Meeting 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120585206/en/ Her Royal Highness Princess Reema Bandar Al-Saud, Ambassador of the Kingdom of Saudi Arabia to the United States of America, speaks on human capital and youth empowerment during the opening Saudi House session at the World Economic Forum Annual Meeting 2026 (Photo: AETOSWire) Speaking on a Saudi House panel, HRH commented: “Human capital today is the key driver if you want a competitive modern economy.” She added: “If you empower people and you give them the space to lead, they will take that drive and they will deliver. And when you place the right people in the right place at the r
BPP Signals Next Era of Growth, Unveiling New Global Parent Brand: Lyceum Education Group21.1.2026 10:03:00 CET | Press release
The creation of the new brand reflects the unique global reach of eleven leading education businesses across the UK, Europe, North America and Australia Today marks the launch of Lyceum Education Group, the new parent brand for 11 leading specialist education businesses across the UK, mainland Europe, Canada and Australia. Lyceum Education Group brings together leading specialist education providers, delivering a diverse portfolio of programmes to benefit learners and businesses globally. From its beginnings as BPP almost 50 years ago, to the creation of the Lyceum Education Group brand today, the move reflects the transition to become a leading, global education group, which will be the second largest post-secondary provider in the UK, and the fourth largest in Europe. Since its acquisition by TDR Capital in 2021, the Group has been acquiring new brands which encompass increased specialisms, diversifying its product ranges and entering new global markets. A clear focus for Lyceum Educ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom